Targeted Protein MRI Contrast Agents for Tumor-Specific Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved contrast agents for Magnetic Resonance Imaging (MRI) that enhance imaging specificity and sensitivity by targeting specific cellular markers.
Innovation Solution
Development of protein contrast agents with modified parvalbumin, calmodulin, or CD2 polypeptides containing paramagnetic metal binding sites and targeting moieties, such as PSMA binding peptides, HER2-specific affibodies, or VEGFR binding peptides, linked via flexible peptide linkers, which can be PEGylated to alter hydrophobicity and hydrophilicity, and administered for targeted MRI imaging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional contrast agents are used for MRI, then imaging can be performed, but imaging specificity and sensitivity are insufficient
Solution Approach 1:
The contrast agent incorporates a targeting moiety that confers specific binding properties to particular cellular markers or tissues. This localized functional differentiation enables the agent to concentrate imaging enhancement at specific anatomical sites rather than distributing uniformly throughout the body, thereby improving imaging specificity and sensitivity for targeted regions.
Solution Approach 2:
The contrast agent is constructed as a composite molecule combining a paramagnetic core (providing MRI contrast) with a targeting moiety (providing specific binding capability). This composite structure integrates two distinct functional components into a single agent that simultaneously delivers both contrast enhancement and targeted localization, resolving the contradiction between imaging performance and targeting capability.
2Measurement precision
If contrast agents with targeting moieties are developed, then imaging specificity is improved, but device complexity increases
Solution Approach 1:
The patent merges the contrast-providing component and the targeting component into a single integrated molecular entity. By combining these functions in one agent rather than using separate components, the design achieves improved imaging sensitivity through targeted accumulation while avoiding the operational complexity that would arise from coordinating multiple separate agents.
Solution Approach 2:
The contrast agent is designed with multi-functionality, serving both as an MRI contrast agent and as a targeted binding molecule. This universal design allows a single agent to perform multiple roles (contrast enhancement and specific targeting), reducing the need for separate specialized components and thereby managing complexity while achieving high imaging sensitivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The protein contrast agents provide enhanced imaging specificity and sensitivity by targeting specific cellular markers, improving MRI contrast and allowing for better visualization of tissues and tumors.
Implementation Method 1
the modified parvalbumin polypeptide or the fragment thereof contains a paramagnetic metal binding site consisting of one or more amino acid residues of the modified parvalbumin polypeptide or fragment thereof
Data Source
AI summary
Provided herein are protein contrast agents and targeted protein contrast agents, formulations thereof, and methods of use, including but not limited to, as a magnetic resonance imaging contrast agent.